Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8⁺T cells.

ABSTRACT:

Purpose

Our study intended to explore how low-dose anti-angiogenic drugs affected anti-tumor immunity of tumor-infiltrating exhausted CD8⁺T cells and achieved better clinical response when combined with immunotherapy. We set out to find potential targets or predictive biomarker on CD8⁺T cells for immunotherapy.

Methods

We tested different doses of anti-VEGFR2 antibody combined with anti-PD1 antibody to treat LUAD in vivo and analyzed tumor-infiltrating CD8⁺T cells by flow cytometry. CD8⁺T cells overexpressing LAYN were co-cultured with LA795 cell lines to identify the function of LAYN in CD8⁺T cells. We also analyzed clinical samples from advanced LUAD patients treated with anti-angiogenesis therapy combined with immunot

SUBMITTER: Yang B 

PROVIDER: S-EPMC9747853 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature